Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: Effects on ovarian function, disease-free survival, and overall survival

Breast Cancer Research and Treatment

Volumn 168, Issue 3, 2018, Pages 679-686

  Zhang, Ying ^a,b   Ji, Yajie ^c   Li, Jianwei ^a,b   Lei, Li ^d   Wu, Siyu ^a,b   Zuo, Wenjia ^a,b   Jia, Xiaoqing ^a,b   Wang, Yujie ^a,b   Mo, Miao ^a,b   Zhang, Na ^e   Shen, Zhenzhou ^a,b   Wu, Jiong ^a,b   Shao, Zhimin ^a,b   Liu, Guangyu ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d KUNMING MEDICAL UNIVERSITY   (China)

^e Division of Minimally Invasive Gynecology   (China)

Author keywords

Breast cancer; ER positive; GnRHa; Ovarian preservation; Premenopausal

Indexed keywords

GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; TAMOXIFEN; TOREMIFENE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; GONADORELIN;

ADULT; AMENORRHEA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARIAN PRESERVATION; OVARY FUNCTION; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; WILCOXON SIGNED RANKS TEST; ADJUVANT CHEMOTHERAPY; ADOLESCENT; AGONISTS; BREAST TUMOR; CLINICAL TRIAL; DRUG EFFECT; GENETICS; MIDDLE AGED; OVARY FOLLICLE; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MIDDLE AGED; OVARIAN FOLLICLE; PREMENOPAUSE; PROGRESSION-FREE SURVIVAL; RECEPTORS, ESTROGEN; YOUNG ADULT;

EID: 85041239142     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-018-4660-y     Document Type: Article

References (23)

1. Anders CK, Johnson R, Litton J et al (2009) Breast cancer before age 40 years. Semin Oncol 36:237–249
2. Ewertz M, Jensen AB (2011) Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol 50:187–193
3. Jain S, Santa-Maria CA, Gradishar WJ (2015) The role of ovarian suppression in premenopausal women with hormone receptor-positive early-stage breast cancer. Oncology (Williston Park) 29(473–478):481
4. Moore HC, Unger JM, Phillips KA et al (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923–932
5. Del ML, Boni L, Michelotti A et al (2011) Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306:269–276
6. Lambertini M, Ceppi M, Poggio F et al (2015) Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol 26:2408–2419
7. Lambertini M, Del ML, Pescio MC et al (2016) Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med 14:1
8. Francis PA, Regan MM, Fleming GF et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436–446
9. Pagani O, Regan MM, Walley BA et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107–118
10. Petrek JA, Naughton MJ, Case LD et al (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24:1045–1051
11. Iwase A, Nakamura T, Nakahara T et al (2015) Anti-Mullerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review. Reprod Sci 22:519–526
12. Qiu L, Fu F, Huang M et al (2016) Evaluating the survival benefit following ovarian function suppression in premenopausal patients with hormone receptor positive early breast cancer. Sci Rep 6:26627
13. Francis PA, Regan MM, Fleming GF et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436–446
14. Song G, Gao H, Yuan Z (2013) Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol 30:667
15. Sverrisdottir A, Nystedt M, Johansson H, Fornander T (2009) Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117:561–567
16. Leonard R, Adamson D, Anderson R et al (2010) Hormone levels in the option trial show no ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer—an anglo-celtic collaborative group and NCRN trial. Cancer Res. http s://doi. org/10.1158/0008-5472.SABCS10-P5-13-07
17. Munster PN, Moore AP, Ismail-Khan R et al (2012) Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 30:533–538
18. Gerber B, von Minckwitz G, Stehle H et al (2011) Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 29:2334–2341
19. Li J, Liu G, Yu K et al (2015) Effect of using LHRH analog during chemotherapy (CT) on premature ovarian failure and prognosis in premenopausal patients with early-stage, hormone receptor-positive breast cancer: the primary analysis of a randomized controlled phase III trial. Cancer Res. http s://doi.org/10.1158/1538-7445.SABCS14-P1-12-02
20. Swain SM, Jeong JH, Geyer CJ et al (2010) Longer therapy, iat-rogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053–2065
21. Lambertini M, Boni L, Michelotti A et al (2015) Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA 314:2632–2640
22. Regan MM, Walley BA, Francis PA et al (2017) Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225–2232
23. Lambertini M (2017) Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients. In: San Antonio breast cancer symposium 2017, San Anotonio, The United States